Contact Sales Technical Support

Luxcel Biosciences and HD Biosciences Enter Collaboration Agreement for Mitochondria Toxicity & Metabolism Assays for Preclinical Drug Safety Evaluation

Luxcel Biosciences and HD Biosciences Enter Collaboration Agreement for Mitochondria Toxicity & Metabolism Assays for Preclinical Drug Safety Evaluation

Cork, Ireland and Shanghai, China March 1st, 2017

Luxcel Biosciences Ltd (Luxcel), a Cork based Biotechnology Company and HD Biosciences Co., Ltd. (HDB), a leading preclinical drug discovery Contract Research Organization (CRO), announced today that they have entered a strategic partnership to co‐market and provide new assay technologies for preclinical drug safety services. Under the agreement, HDB will gain access to Luxcel’s state‐of‐the‐art assays and technologies for assessment of mitochondrial function, toxicity and metabolism.

Mitochondrial dysfunction is a major contributor to drug‐induced toxicity, post‐market drug withdrawal and black box warnings for hepatic and cardiac toxicity. A major focus of the collaboration is the Respirometric Screening Technology (RST/OCR) assay, originally developed by Luxcel in collaboration with Pfizer Inc. (Ref: Will, Y et al (2006) Nature Protocols). A significant advance of the RST assay, versus the commonly used Glu/Gal assay, is its ability to accurately differentiate specific mitochondrial toxicity from non‐specific toxicity, as well as un-couplers of mitochondrial function from inhibitors. The RST assay is fully validated in high throughput format and in weekly production mode at HDB, Shanghai, providing clients with the best mitochondrial toxicity assay available with cost effective and quick turnaround service.

“We are delighted to team up with Luxcel Biosciences Ltd, a leader in the field of optical sensing technologies.” “HDB offers a full range of in vitro toxicology services including safety profiling panels (Safety Assess™), as well as cardiotoxicity, hepatotoxicity, genotoxicity and cytotoxicity screenings. Luxcel’s growing portfolio of proprietary mitochondria toxicity, bioenergetics & metabolism assays, is highly complementary to our current offerings and provides early and effective identification of mitochondrial liabilities for our client’s drug discovery programs.” stated Dr. Peiyuan Lin, Senior VP of R&D Services of HDB.

“HDB has established and maintained a professional reputation globally with its pre‐clinical service, bringing their clients the most up to date and valuable assays and tools to advance the drug discovery process. This joint effort will leverage the extensive expertise and capabilities from both sides, for the benefit of global as well as China‐based pharmaceutical and biotech companies.” said Dr. Ian Hayes, Commercial Director for Luxcel.

 

About HD Biosciences

HD Biosciences Co., Ltd. is a biology‐focused preclinical drug discovery contract research organization (CRO) with headquarter in Shanghai, and operation facilities in Beijing and San Diego, USA. The company offers comprehensive research and development services to global pharmaceutical and biotech industries around target validation, plate‐based pharmacology, hit identification & lead discovery, therapeutic antibody discovery, in vivo pharmacology, and other related areas. The company currently collaborates with eight (8) of the ten (10) largest pharmaceutical companies in the world and has established strategic partnerships with impacts to their portfolios. The strong scientific expertise, high quality of the services, consistency in deliveries, and constantly meeting or exceeding expectations, have helped the company to earn an excellent reputation in the industry. The in vitro pharmacology R&D and other core competencies of the company are widely recognized as one of the best among preclinical CROs.

About RST/OCA Assay

Please visit: http://www.hdbiosciences.com/EngRST.html

partner